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Abstract 
Introduction: Cell surface thiol isomerase enzymes, principally protein disulphide 
isomerase (PDI), have emerged as important regulators of platelet function and 
tissue factor activation via their action on allosteric disulphide bonds. Allosteric 
disulphides are present in other haemostasis-related proteins, and we have therefore 
investigated whether thiol isomerase inhibition has any influence on two endothelial 
activities relevant to haemostatic regulation, namely activation of protein C and 
activation of plasminogen, with subsequent fibrinolysis.  
Materials and Methods: The study was performed using the human microvascular 
endothelial cell line HMEC-1. Thiol isomerase gene expression was measured by 
RT-PCR and activation of protein C and plasminogen by cell-based assays using 
chromogenic substrates S2366 and S2251, respectively. Cell mediated fibrinolysis 
was measured by monitoring absorbance at 405 nm following fibrin clot formation on 
the surface of HMEC-1 monolayers. 
Results and Conclusions: A variety of thiol isomerase enzymes, including PDI, 
were expressed by HMEC-1 cells and thiol reductase activity detectable on the cell 
surface was inhibited by both RL90 anti-PDI antibody and by the PDI inhibitor 
quercetin-3-rutinoside (rutin). In cell-based assays, activation of plasminogen, but 
not of protein C, was inhibited by RL90 antibody and, to a lesser extent, by rutin. 
Fibrin clot lysis occurring on a HMEC-1 monolayer was also significantly slowed by 
RL90 antibody and by rutin, but RL90-mediated inhibition was abolished in the 
presence of exogenous tissue plasminogen activator (tPA). We conclude that thiol 
isomerases, including PDI, are involved in fibrinolytic regulation at the endothelial 
surface, although not via a direct action on tPA. These findings broaden 
understanding of haemostatic regulation by PDI, and may aid in development of 
novel anti-thrombotic therapeutic strategies targeted via the fibrinolysis system.  
 
 
Keywords 
Thiol isomerase; Protein disulphide isomerase; protein C; plasminogen; fibrinolysis; 
endothelium. 
 
3 
 
Introduction 
 “Allosteric disulphide bonds” are involved in the functional regulation of a number of 
haemostatic proteins. The most closely studied examples are those in tissue factor 
and in integrin β3.  Both proteins contain at least one disulphide bond with the –
RHStaple configuration characteristic of allosteric disulphides, and redox alteration of 
the thiol/disulphide status of these bonds regulates the haemostatic function of the 
protein [1]. Proteomic studies have identified the presence of similar –RHStaple 
disulphides in a number of other haemostatically relevant proteins located on the 
surface of platelets (glycoprotein 1bα) and on cells of the vascular wall 
(thrombomodulin, uPA receptor), as well as in blood plasma (fibrinogen, 
plasminogen, tPA, uPA) [2]. Redox regulation of allosteric disulphides may therefore 
play a wider role in haemostatic control than previously realised. 
Protein disulphide isomerase (PDI), a 57kD member of the thioredoxin superfamily of 
oxidoreductases, functions primarily within the endoplasmic reticulum as a protein 
folding catalyst and chaperone, by virtue of its ability to bring about the formation, 
reduction or isomerisation of disulphide bonds [3]. PDI also resides outside the 
endoplasmic reticulum, at a variety of sites which include the exofacial surface of the 
plasma membrane [4], where it is available for regulation of allosteric disulphide 
bonds in proteins of the haemostasis system. Activated platelets release PDI and a 
pool of PDI is found at the platelet cell surface [5]. More recently it has become clear 
that a range of thiol isomerase enzymes (including PDI, ERp57 and ERp5) become 
available at the platelet surface following activation [6]. Experiments using mouse 
models of thrombus formation have highlighted a critical role for PDI [7-9], or its 
close homologue ERp57 (10), in platelet accumulation and fibrin deposition [11] . 
PDI associates with tissue factor and targets the allosteric cys186-cys209 disulphide 
bond [12]. An alternative mechanism for the action of PDI on tissue factor is via 
modulated exposure of phosphatidylserine (PS) on the cell surface, since PDI has 
been shown to increase PS internalisation by affecting both flippase and floppase 
enzymes [13]. 
Although the functional role of cell surface PDI on platelets and tissue factor is 
established, its relevance to endothelial regulation of haemostasis is less well 
studied. This is an important question to address because of the crucial 
antithrombotic role played by healthy endothelium. PDI is present inside endothelial 
cells and is up-regulated under conditions of hypoxia [14-16]. Endothelial cells in 
culture also express PDI on their exofacial surface, and this PDI regulates the 
adhesive properties of both thrombospondin [17] and of its binding partner integrin 
αV β3 [18]. In contrast, experiments performed using mouse models of thrombus 
formation indicate that, in vivo, PDI is not expressed on the surface of unperturbed 
vessel wall, but that it accumulates rapidly following vascular injury by binding to  β3 
integrins [7,8,19].  
In this study we have used the human endothelial cell line HMEC-1 [20,21] as a 
model in which to investigate the possible role of cell surface thiol isomerase 
enzymes, including PDI, in two important aspects of endothelial regulation of 
haemostasis, namely protein C activation and plasminogen activation with 
subsequent fibrin lysis. Our initial aim was to identify thiol isomerase enzyme 
expression  by HMEC-1 endothelial cells and to determine whether enzyme activity 
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is detectable on their surface. We then investigated whether thiol isomerase 
inhibition was associated with alteration of protein C and plasminogen activation on 
the surface of these cells. 
 
Materials and Methods 
Materials 
Human protein C (Cambridge Biosciences), human tissue plasminogen activator 
(tPA) (Calbiochem), RL90 anti-PDI antibody and IgG2a isotype control (Thermo 
Scientific), anti- tPA tissue plasminogen activator antibody, Clone T1 (Thermo 
Scientific  and Abcam) and chromogenic substrates S2366 and S2251 
(Chromogenix) were obtained from the sources shown. All other reagents were 
purchased from Sigma-Aldrich. Assays were performed in HEPES buffered saline 
(HBS) containing NaCl 140 mmol/L, KCl 2.7 mmol/L, glucose 5 mmol/L and HEPES 
10 mmol/L, pH 7.3. The PDI inhibitor molecule quercetin-3-rutinoside (rutin) was 
prepared by dissolving to a concentration of 200 mM in dimethyl sulphoxide, followed 
by dilution in HBS to a final concentration in experiments of 100 µΜ. Dulbeccos 
Modified Eagle Medium and other cell culture reagents were purchased from 
Invitrogen, as were all molecular biology materials. 
 
Methods 
Cell culture 
Human microvascular endothelial cells (HMEC-1) were kindly provided by Dr Ian 
Locke, University of Westminster. HMEC-1 cells were cultured in Dulbeccos Modified 
Eagle Medium (DMEM) containing fetal calf serum (10%), penicillin (100 U/mL), 
streptomycin 0.1 mg/mL) and glutamine (2 mmol/L). For assays of protein C 
activation, plasminogen activation and fibrin lysis cells were plated on colourless cell 
culture treated 96 well plates and used at 80-90% confluency. For assays of PDI 
activity cells were plated on cell-culture treated black 96 well plates. 
 
RT-PCR to determine thiol isomerase gene expression in HMEC-1 cells 
HMEC-1 cells were cultured to 90% confluency in 6 well dishes. Total RNA was 
extracted using TriZol reagent (Invitrogen) and cDNA was synthesised using the 
MMLV reverse transcriptase and random primers (negative controls included RNA 
without MMLV to check for genomic DNA contamination). Primer sequences for the 
PDI, PDIp, EndoPDI, ERp5 and ERp57 are described in Table 1. PCR reactions 
contained 0.5 pmol/L forward and reverse primers, Taq polymerase 0.02 U/µl, 
dNTPs 0.1 mmol/L, MgCl2 1.5 mmol/L in 10 mmol/L Tris-HCl pH9.0 and cycles for all 
amplifications were 95oC for 5 minutes followed by 40 cycles: (94oC for 20 sec, 55oC 
for 20 sec, and 72oC for 30 sec) except for P4HB (PDI) where the extension step 
was increased to 1 minute in each cycle. PCR products were separated on 2% 
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agarose gel stained with ethidium bromide with a 100bp ladder (Norgene 100-
5000bp). 
 
Gene name Strand Primers sequence 5'→ 3' Product size (bp) 
β-actin Forward AGCCATGTACGTAGCCATCC  
      220  
  Reverse CTCTCAGCTGTGGTGGTGAA   
        
PDIA6 Forward GGTCTGGTGAGCTGTACCTTC  
 (ERp5)     369  
  Reverse ACTCAGCGCAGCATCTACAA   
        
PDIA3 Forward CACGGACGACAACTTCGAGA  
 (ERp57)    340  
  Reverse TTCCTCAGTCCTGAGAGGCA   
        
TXNDC5 Forward TACACGGCCGACATGTTCAC  
 (EndoPDI)     412  
  Reverse CGTGCAGCTCAAAGTTGCTT   
        
P4HB Forward TGCCCCTTGTCATCGAGTTC  
 (PDI)     620  
  Reverse GAAGCTGTGCACTTTGACGG   
        
    
PDIA2 Forward CTTCTGGCCCCCTTATCTGC  
 (PDIp)     396  
  Reverse ACTCCGTCACACCAAACTCC   
        
Table 1: Primer sequences and expected product sizes for human thiol isomerases.  
 
 
Measurement of cell surface disulphide reductase activity of PDI:  
Disulphide reductase activity was measured by fluorescence assay using the 
pseudosubstrate dieosin glutathione disulphide (Di-E-GSSG), as previously 
described [22]. The inhibitory effect of RL-90 antibody (100 µg/mL) was measured by 
comparison against isotype control, following pre-incubation with HMEC-1 cells for 
30 minutes at 37oC. In a similar way, the effect of rutin (100 µΜ) was measured by 
comparison against vehicle control. 
HMEC-1 viability following pre-incubation of cells with thiol-isomerase inhibitor 
molecules for 30 minutes was determined by MTT assay [23].  
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Measurement of protein C activation and plasminogen activation on HMEC-1 
monolayers:  
The effect of PDI inhibition on (a) activation of protein C and (b) activation of 
plasminogen, was measured using chromogenic cell-based assays, essentially as 
described by Sandusky et al. [24] and Wileman et al. [25], respectively.  
For measurement of protein C activation, HMEC-1 cells were washed once with HBS 
and then incubated for 60 minutes with 25 µg/mL human protein C and 0.5 units /mL 
human thrombin in HBS containing 5 mmol/L CaCl2. Aliquots (75 µL) of this mixture 
were then transferred to microplate wells containing 50 µL of hirudin (10 units/mL), 
mixed and incubated for a further 5 minutes, after which chromogenic substrate 
S2366 (final concentration 0.5 mmol/L) was added and absorbance at 405 nm 
monitored over a period of 120 minutes. All incubations were carried out at 37oC. To 
determine the effect of PDI inhibition, RL-90 anti-PDI antibody or isotype control 
(both 100 µg/mL) were included in the initial incubation mixture between HMEC-1 
cells, protein C and thrombin.  
For measurement of plasminogen activation, HMEC-1 cells were washed once with 
HBS and then incubated at 37oC for 30 minutes with either RL-90 anti-PDI antibody 
or isotype control (both 100 µg/mL). Similar incubations were performed using rutin 
(100 µΜ) or vehicle control. Human plasminogen (2 µmol/L) was then added and, 
after a further 10 minutes incubation, chromogenic substrate S2251 (final 
concentration 0.5 mmol/L) was added and absorbance at 405 nm monitored over a 
period of 120 minutes. All incubations were carried out at 37oC.  
To further investigate the role of PDI in plasminogen activation, experiments were 
performed on washed HMEC-1 cells with addition of either bovine PDI or ovalbumin 
(as an inert protein control), at final concentrations of 1.75 µM. 
 
Measurement of fibrin lysis on HMEC-1 monolayers 
Cell-mediated lysis of fibrin clots was measured using a modification of the method 
described by Wileman et al. [25]. Briefly, HMEC-1 monolayers grown in 96 well 
microplates were washed once with HBS prior to addition of plasminogen (0.28 
µmol/L), CaCl2 (5.3 mmol/L), human thrombin (0.4 units/mL) and human fibrinogen 
(1 mg/mL). After mixing the absorbance at 405 nm was monitored for a period of 4.5 
hours.  
The role of tissue plasminogen activator (tPA) in this experimental system was 
investigated by performing experiments following pre-incubation of washed HMEC-1 
cells for 30 minutes with anti-tPA antibodies or isotype control (both 100 µg/mL), 
prior to addition of the other reagents. All incubations were carried out at 37oC.  
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To determine the effect on fibrin lysis of PDI inhibition, HMEC-1 cells were pre-
incubated for 30 minutes with RL-90 anti-PDI antibody or isotype control (both 100 
µg/mL). Similar experiments were performed using rutin (100 µΜ) or vehicle control.  
To investigate in more detail the effects of RL90 antibody on the fibrinolytic process, 
further experiments were performed using an identical protocol, but this time with the 
addition of tissue plasminogen activator (0.05 ng/mL).  
 
 
Statistical methods 
Data from experiments to investigate the effect of thiol isomerase inhibition on 
protein C and plasminogen activation were obtained as sequences of absorbance 
readings over the first 120 minutes of each experiment. To measure fibrin lysis, 
sequential absorbance values were measured between 0.5 hours (completion of 
thrombin-induced fibrin formation) and 4.5 hours (completion of fibrinolysis process). 
In all cases, data were fitted to a sigmoidal model and comparison of curves 
performed by F test using Graphpad Prism software. A p value of <0.05 was taken 
as evidence of statistical significance. Thiol reductase activity was compared to the 
appropriate control using student T-test. 
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Results 
Thiol isomerase expression in HMEC-1 cells 
The HMEC-1 cells were found to express ERp5, ERp57, EndoPDI and P4HB (PDI) 
by RT-PCR. PDIA2, which has been previously described in placenta was not 
detectable in the HMEC-1 cells (Fig 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Thiol isomerase expression in HMEC-1 cells. RT-PCR Gene expression of 
β-actin (220bp), ERp5 (369bp), ERp57 (340bp), EndoPDI (412bp), P4HB (620bp), 
no PDIA2 product was detected. Products were separated on 2% agarose gel 
stained with ethidium bromide. 
 
 
Ladder 
β-actin   ERp5  ERp57   EndoPDI  P4HB PDIA2
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Thiol isomerase activity in HMEC-1 cells 
A small but consistent disulphide reductase activity was detected on the surface of 
the HMEC-1 cells and this was significantly inhibited by both RL90 anti-PDI antibody 
(100 µg/mL) and by rutin (100 µM) (Fig 2). The thiol isomerase inhibitors caused no 
significant reduction in cell viability (as measured by MTT assay) compared with the 
appropriate controls (data not shown), therefore the inhibition was not due to 
increased cell death. 
 
 
Figure 2. Inhibition of disulphide reductase activity on HMEC-1 cells by RL90 anti-
PDI antibody (100 µg/mL) and by rutin (100 µM). Enzyme activity was measured by 
fluorescence assay using the pseudosubstrate dieosin glutathione disulphide. Data 
represent mean and SEM values from 5-10 experiments, *p<0.05 by student T-test. 
 
 
Effects of PDI inhibition on protein C activation and plasminogen activation on 
HMEC-1 monolayers 
In the absence of cells there was almost no colour generation from chromogenic 
substrates S2366 (activated protein C) and S2251 (plasmin), indicating minimal non-
specific activation of either protein C or plasminogen under the experimental 
conditions employed. In contrast, in the presence of a HMEC-1 cell monolayer, there 
was a steady increase in absorbance at 405 nm over a period of 120 minutes. In 
experiments performed using S2366 (activated protein C), no difference was 
observed between results obtained in the presence of RL90 anti-PDI antibody and 
isotype control (Fig 3A), however using S2251 (plasmin) the increase in absorbance 
was significantly reduced  by RL90 antibody compared with isotype control (p < 
0.001) (Fig 3B). In a similar way, plasminogen activation, measured using S2251 
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(plasmin), showed a small but statistically significant inhibition in the presence of 
rutin (100 µM) (p <0.05) (Fig 4A). Addition of exogenous bovine PDI (1.75 µM) 
caused a small but significant increase in plasminogen activation (p<0.05) (Fig 4B). 
 
Figure 3. Protein C activation (A) and plasminogen activation (B) occurring on HMEC-1 
endothelial cells in the presence of RL-90 anti-PDI antibody, or isotype control (both 100 
µg/mL). Results display cell-mediated activity only (any non-specific activity has been 
subtracted).  No significant difference was observed in protein C activation (RL90 and 
isotype control values fit to the same curve), however plasminogen activation is significantly 
inhibited by RL-90 (p<0.001 by F test). Data represent mean and SEM (n = 6). 
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Figure 4: Plasminogen activation occurring on HMEC-1 endothelial cells in the presence 
of rutin (100 µM) or vehicle control (A) and the presence of exogenous bovine PDI or 
ovalbumin (both 1.75 µM) (B). Results display cell-mediated activity only (any non-specific 
activity has been subtracted). Data represent mean and SEM (n = 8). Treatments were 
significantly different to their relevant control in both (A) and (B) (p<0.05) when compared 
using sigmoid curve fit comparison and F test. 
 
Effects of PDI inhibition on fibrin lysis on HMEC-1 monolayers 
Conversion of fibrinogen to fibrin following addition of thrombin was reflected in a rise 
in absorbance during the first 30 minutes of the experiments. Following a plateau 
phase absorbance values fell as fibrin lysis occurred. Lysis curves showed a 
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significant shift to the right in the presence of anti-tPA antibodies (Fig 5A), confirming 
the role of tPA in this experimental model. 
In the presence of both rutin (Fig. 5B) and RL90 antibody (Fig. 5C) there was a 
significant shift to the right in lysis curves, compared with relevant controls, indicating 
inhibition of fibrinolysis following blockade of thiol isomerise activity.  
When RL90 experiments were repeated with the addition of human tPA to the 
system, there was no difference between fibrin lysis occurring in the presence of 
RL90 or isotype control (Fig 5D). 
 
 
Figure 5.  Fibrin lysis occurring on HMEC-1 endothelial cells in the presence of A: 
anti-tPA antibody from two sources, compared with isotype control (all 100 µg/ml); B: 
rutin (100µM) and vehicle control; C: RL-90 anti-PDI antibody or isotype control (both 
100 µg/ml)  in the absence of exogenous human tissue plasminogen activator; D: 
RL-90 anti-PDI antibody or isotype control (both 100 µg/ml) in the presence of 
exogenous human tissue plasminogen activator (0.05 ng/mL). In A-C curves were 
significantly different from their appropriate controls (p<0.01) when analysed using 
sigmoid curve fit comparison and F test but in D no significant difference was found 
and both RL90 and control data fit to a single curve. Data represent mean and SEM 
(n = 8). 
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Discussion 
The major findings of this study are that inhibition of thiol isomerase activity on the 
endothelial surface resulted in diminished plasminogen activation and subsequent 
fibrin lysis. In contrast, there was no loss of protein C activation caused by thiol 
isomerase inhibition, indicating firstly that this aspect of endothelial haemostatic 
regulation is not thiol isomerase-dependent and secondly that the observations on 
plasminogen activation were not simply due to a non-specific effect.  
The fibrinolytic mechanism plays a key antithrombotic role via clearance of fibrin 
from the vascular system. Understanding its detailed mechanism is therefore 
important in preventing and treating cardiovascular disease. Fibrin is degraded by 
the serine protease plasmin, derived from the inactive proenzyme plasminogen 
which is found circulating in blood plasma. Two main types of plasminogen activator 
are recognised: tissue-type (tPA) and urokinase type (uPA) plasminogen activator, 
with tPA generally considered the more important initiator of fibrin clearance in the 
circulation. In our experiments, we have not distinguished between the two, however 
we found fibrin lysis was significantly inhibited by anti-tPA antibodies, indicating that 
tPA plays a major role in this experimental model. 
Vascular fibrinolysis is a highly regulated process requiring appropriate interactions 
between the various components (plasminogen, tPA, inhibitor molecules).  These 
interactions are optimised by binding of the key proteins to relevant surfaces, either 
the surface of a fibrin clot or the surface of endothelial cells lining the blood vessel 
[26]. Recent research has identified the annexin A2 heterotetramer (AIIt), comprising 
two molecules of annexin A2 and two of the protein S100A10, as the key endothelial 
receptor bringing together both plasminogen and tPA to optimise plasmin generation 
at the surface of the vascular wall [27]. Annexin A2 binds to anionic phospholipids, 
chiefly phosphatidylserine (PS) [28], and thus anchors the S100A10 subunits to the 
membrane, where they act to co-localise plasminogen and tPA. 
In our experiments measuring fibrin lysis (in the absence of added tPA), the rate of 
fibrin lysis was significantly diminished in the presence of thiol isomerase inhibitor 
molecules (RL90 and rutin), indicating that fibrinolytic regulation at the cell surface is, 
at least to some extent, dependent upon intact thiol isomerise activity. In contrast, 
when tPA was added to the system the inhibitory effect of RL90 was lost, suggesting 
that the effect of thiol isomerase inhibition was not targeted at the tPA molecule 
itself, but rather at the mechanism by which endothelium either releases 
plasminogen activator or else binds to tPA and /or other fibrinolytic components, in 
order to optimise the catalytic efficiency of fibrinolysis on the cell surface. Thiol 
isomerases may alter allosteric disulphides in a component of the AIIt heterotetramer 
to which tPA binds on the endothelial surface. Alternatively, PDI-mediated alteration 
of PS exposure [13] may destabilise the anchoring of AIIt by annexin A2, and thus 
diminish endothelial surface plasminogen activation. 
Another possible interpretation of our results may involve thiol isomerase-mediated 
redox alteration of the plasmin molecule itself, which is known to undergo reduction 
and proteolysis to the fibrinolytically-inactive product “angiostatin”. This is less likely 
to explain our results however, since plasmin reduction is mediated by 
phosphoglycerate kinase [29], not by PDI [30], and occurs on the surface of vascular 
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smooth muscle, but not on endothelial cells [31]. An alternative mechanism proposes 
reduction of plasmin by the AIIt receptor itself, in a system involving electron transfer 
from NADPH via thioredoxin [32]. 
Thiol isomerase enzymes are sensitive to redox conditions and for isomerases 
located on the surface of blood cells and endothelium, the thiol/disulphide balance of 
redox couples within blood plasma, principally reduced and oxidised glutathione and 
cysteine, will strongly influence enzyme activity [33]. The extracellular redox 
environment is recognised as an important regulator of both platelet function [34,35] 
and endothelial biology [36] and changes in plasma redox state occur in conditions 
characterised by increased cardiovascular risk [37]. Our findings suggest that 
alteration in fibrinolysis may be a further aspect of deranged vascular biology in 
these conditions. 
We detected mRNA expression of a variety of thiol isomerase enzymes in the 
HMEC-1 cell line and this highlights the likelihood that PDI is not the sole member of 
the thiol isomerase family to be involved in redox regulation of proteins at the 
endothelial surface. In our experiments, plasminogen activation and fibrin lysis were 
inhibited by RL90 antibody, which is known to cross react with ERp57 [10], but also 
(to a lesser degree) by rutin, which is a more specific inhibitor of PDI [38]. Addition of 
exogenous PDI produced a statistically significant increase in the rate of 
plasminogen activation. The fact that the effects on plasminogen activation of either 
rutin or exogenous PDI were smaller than those of RL90 is consistent with a model 
in which PDI does not act alone, but rather contributes to the overall action of a wider 
range of thiol isomerase enzymes.  
Taken together, our results therefore identify thiol isomerase activity, including PDI,  
as an important factor influencing fibrinolysis on the endothelial surface, adding 
another dimension to the growing importance of this enzyme in the control of 
haemostasis and vascular inflammation [39]. A number of small molecule inhibitors 
of PDI have recently been identified by high-throughput screening and are being 
proposed as a new class of antithrombotic drugs [40]. This prospect is enhanced by 
evidence that the safety profile of PDI inhibitors may be better than that of existing 
antithrombotics since PDI appears to be essential for thrombus formation but not for 
normal haemostasis [41].  
Conclusions 
On the endothelial surface thiol isomerase enzymes, including PDI, appear to be 
required for plasminogen activation and fibrin lysis, although not via a direct action 
on t-PA. In contrast, protein C activation is not thiol isomerase-dependent. These 
findings broaden the scope of thiol isomerase involvement in haemostatic regulation 
and increase the knowledge base when considering the use of PDI inhibitors in anti-
thrombotic therapy. 
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